<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82298">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01907048</url>
  </required_header>
  <id_info>
    <org_study_id>16167</org_study_id>
    <secondary_id>XA1202</secondary_id>
    <nct_id>NCT01907048</nct_id>
  </id_info>
  <brief_title>Patient and Physician Knowledge of Key Safety Messages</brief_title>
  <official_title>Xarelto (Rivaroxaban) - Risk Minimisation Plan Evaluation: Patient and Physician Knowledge of Key Safety Messages</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C., RTI Health Solutions</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This cross-sectional epidemiologic study will measure physician and patient awareness and
      understanding of the key messages in the Xarelto prescriber guide and Xarelto patient alert
      card.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Knowledge and understanding among physicians regarding key safety information contained in the prescriber guide assessed by web-based questionnaire</measure>
    <time_frame>Up to 18 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Knowledge and understanding of patients regarding the key safety information contained in the patient alert card assessed by paper-based questionnaire</measure>
    <time_frame>Up to 18 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Anticoagulation</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Rivaroxaban (Xarelto, BAY59-7939)</intervention_name>
    <description>Survey to measure physician awareness and understanding of the key messages in the prescriber guide.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Rivaroxaban (Xarelto, BAY59-7939)</intervention_name>
    <description>Survey to measure patient awareness and understanding of the key messages in the patient card.</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Physicians of various specialties; patients treated in primary care and specilized
        clinical practices.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Physicians eligibility:

          -  Prescription of rivaroxaban in the past 6 months for adult patients for the
             Prevention of stroke and systemic embolism with non-valvular atrial fibrillation
             (SPAF) or Treatment of deep venous thrombosis (DVT) and prevention of recurrent DVT
             and pulmonary embolism (PE) following an acute DVT.

        Patient eligibility:

          -  Use of rivaroxaban for SPAF or DVT within the previous 3 months; aged 18 years and
             above; able to understand and complete the consent form and patient questionnaire.

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <email>clinical-trials-contact@bayerhealthcare.com</email>
  </overall_contact>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 27, 2014</lastchanged_date>
  <firstreceived_date>June 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Survey</keyword>
  <keyword>Effectiveness of risk minimization measures</keyword>
  <keyword>Rivaroxaban</keyword>
  <keyword>Anticoagulants</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
